Financial Performance - BriaCell Therapeutics Corp. reported a net loss of $6.12 million for the three months ended April 30, 2025, compared to a net loss of $1.72 million in the same period of 2024[109]. - The company reported a loss of $6,224,929 for the three-month period ended April 30, 2025, compared to income of $1,692,242 in 2024, driven by a significant decrease in non-cash gains[117]. - The company reported a net loss of $18,392,033 for the nine-month period, compared to a loss of $3,682,796 in 2024, primarily due to a smaller gain on the fair value of the warrant liability[127]. Operating Expenses - Total operating expenses decreased to $6.33 million in Q2 2025 from $9.23 million in Q2 2024, primarily due to reduced research, development, and clinical trial expenses[109]. - Total research, development, and clinical trial costs for the three-month period ended April 30, 2025, were $4,810,196, down 37.8% from $7,657,632 in 2024[111]. - Clinical trial expenses for the same period were $3,190,751, a decrease of 26.9% from $4,359,850 in 2024, primarily due to the conclusion of the Bria-IMT™ Phase 1/2a trial[112]. - The Bria-IMT™ Pivotal Phase 3 Study costs amounted to $2,708,394, down 28.1% from $3,764,521 in 2024, reflecting a shift in spending focus[113]. - General and administrative expenses for the three-month period were $1,518,059, slightly down from $1,572,016 in 2024, indicating operational efficiencies[115]. - For the nine-month period ended April 30, 2025, total research, development, and clinical trial costs were $14,160,314, a 38.1% decrease from $22,772,344 in 2024[120]. - Clinical trial expenses for the nine-month period were $9,822,400, down 22.5% from $12,650,189 in 2024, reflecting the completion of the Bria-IMT™ Phase 1/2a trial[121]. Capital Raising and Financial Position - The company raised approximately $3.05 million from a public offering of 762,500 common shares at $4.00 per share in February 2025[94]. - In April 2025, BriaCell closed an underwritten public offering for 3,066,666 units, generating approximately $13.8 million in gross proceeds[105]. - The Company intends to raise additional capital through debt or equity financings to achieve its business objectives[131]. - Certain directors and officers agreed to defer payment of their fees until financing was completed, after which these fees were paid in full[131]. - As of April 30, 2025, the company had total assets of $17,001,798, significantly up from $5,872,261 in July 2024, indicating improved financial position[129]. - The Company achieved a positive working capital balance of $10,454,565 as of April 30, 2025, compared to a negative working capital balance of $3,807,303 on July 31, 2024[142]. - The Company's cash and cash equivalents increased by $11,598,164 from July 31, 2024, to April 30, 2025[132]. - Cash gained in financing activities for the period ended April 30, 2025, was $31,891,239, compared to nil for the period ended April 30, 2024[133]. Clinical Trials and Research Developments - The pivotal Phase 3 study of Bria-IMT™ has enrolled over 75 patients and is expected to complete enrollment by late 2025 or early 2026, with top-line data potentially available in H1 2026[99]. - Bria-OTS™ demonstrated a 100% resolution of lung metastasis in a patient after two months of therapy, confirmed at four months[100]. - BriaCell's Phase 2 study showed a median overall survival of 17.3 months for HR+ metastatic breast cancer patients treated with Bria-IMT™ plus checkpoint inhibitors, outperforming the standard of care, TRODELVY, which had a median survival of 14.4 months[97]. - The company is developing anti-B7-H3 antibodies for multiple cancer indications through its subsidiary, BriaPro Therapeutics Corp.[95]. - BriaCell's ongoing Phase 1/2 study of Bria-OTS™ has cleared safety evaluation and is now transitioning to combination therapy with an immune checkpoint inhibitor[108]. - Positive survival and clinical benefit data from the Phase 2 study were presented at ASCO 2025, indicating potential for FDA approval and commercialization[107]. Risk Management - The Company is exposed to foreign exchange risk due to transactions in Canadian Dollars, but a 5% change in the exchange rate would not have a material effect on total loss[145]. - Management believes that the credit risk concentration with respect to financial instruments is remote[141]. - The Company continues to focus on its Phase 3 Bria-IMT™ pivotal study in advanced metastatic breast cancer while reducing expenditure on non-core activities[131].
BriaCell(BCTX) - 2025 Q3 - Quarterly Report